This is an old revision of this page, as edited by CheMoBot (talk | contribs) at 05:55, 1 July 2011 (Updating {{chembox}} (changes to verified fields - updated 'ChemSpiderID_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEMBL_Ref') per Chem/Drugbox validation (report [[Wikipedia_talk:WikiProject_Ch). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 05:55, 1 July 2011 by CheMoBot (talk | contribs) (Updating {{chembox}} (changes to verified fields - updated 'ChemSpiderID_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEMBL_Ref') per Chem/Drugbox validation (report [[Wikipedia_talk:WikiProject_Ch)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) | |
| Names | |
|---|---|
| IUPAC name 4-Amino-5-fluoro-1-pyrimidin-2-one | |
| Other names Reverset | |
| Identifiers | |
| CAS Number | |
| 3D model (JSmol) | |
| KEGG | |
| PubChem CID | |
| CompTox Dashboard (EPA) | |
SMILES
| |
| Properties | |
| Chemical formula | C9H10FN3O3 |
| Molar mass | 227.19 g/mol |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa).
 N verify (what is ?)
Infobox references
| |
Dexelvucitabine is a failed experimental agent for the treatment of HIV. Dexelvucitabine is a cytidine nucleoside analog and nucleoside reverse transcriptase inhibitor. It was found to inhibit HIV-1 replication in vitro and during Phase II clinical trials, it was found to decrease mean viral load in patients with HIV.
On April 3, 2006, Pharmasset and Incyte Corporation, the pharmaceutical companies developing dexelvucitabine announced the decision to cease further trials and development of the drug due to an increased incidence of grade 4 hyperlipasemia in a phase II trial.
 | This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it. |